Subsidy Information and Financing Scheme MAFRegorafenib Tablet 40 mg 1) Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal... See all × MAFRegorafenib Tablet 40 mg 1) Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumours (GISTs) who have been previously treated with imatinib mesylate. 2) Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. 3) Treatment of patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy. MSHLRegorafenib Tablet 40 mg 1) Treatment of patients with metastatic colorectal cancer who have been previously treated with, o... See all × MSHLRegorafenib Tablet 40 mg 1) Treatment of patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy. 2) Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. 3) Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumours (GISTs) who have been previously treated with imatinib mesylate.
Drug Guidance for Subsidy 02/01/2024 Review of cancer drugs for previously treated advanced hepatocellular carcinoma The Ministry of Health’s Drug Advisory Committee has recommended: Cabozantinib 20 mg, 40 mg a... See all × 02/01/2024 Review of cancer drugs for previously treated advanced hepatocellular carcinoma The Ministry of Health’s Drug Advisory Committee has recommended: Cabozantinib 20 mg, 40 mg and 60 mg tablets; and Regorafenib 40 mg tablet for treating advanced unresectable hepatocellular carcinoma in patients with disease progression after one or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Funding status RRegorafenib 40 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022. RCabozantinib 20 mg, 40 mg and 60 mg tablets are recommended for inclusion on the MAF for the abovementioned indication with effect from 1 September 2022. NRMAF assistance does not apply to any formulations or strengths of ramucirumab, pembrolizumab, nivolumab and ipilimumab when used for previously treated advanced hepatocellular carcinoma. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex. 19/12/2022 Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer The Ministry of Health’s Drug Advisory Committee has recommended: Regorafenib 40 mg tablet fo... See all × 19/12/2022 Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer The Ministry of Health’s Drug Advisory Committee has recommended: Regorafenib 40 mg tablet for treating metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy. Subsidy status RRegorafenib 40 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022. NRMAF assistance does not apply to any formulations or strengths of trifluridine/tipiracil. Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex. 19/12/2022 Review of cancer drugs for previously treated advanced gastric cancer The Ministry of Health’s Drug Advisory Committee has recommended: Nivolumab 40 mg/4 mL and 10... See all × 19/12/2022 Review of cancer drugs for previously treated advanced gastric cancer The Ministry of Health’s Drug Advisory Committee has recommended: Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion for treating patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after two or more prior systemic therapies in line with the following criteria: Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for unresectable locally advanced or recurrent gastric or GEJ cancer; and Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. Subsidy status RNivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022. NRMAF assistance does not apply to any formulations or strengths of pembrolizumab, ramucirumab, regorafenib or trifluridine/tipiracil when used for previously treated advanced gastric cancer. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 40 mg Khoo Teck Puat Hospital National Cancer Centre Ng Teng Fong General Hospital National University Hospital Tan Tock Seng Hospital